Literature DB >> 17657731

Cyclooxygenase-2 mRNA expression correlates with aromatase expression in human breast cancer.

M Salhab1, G Singh-Ranger, R Mokbel, F Jouhra, W G Jiang, K Mokbel.   

Abstract

INTRODUCTION: The cyclooxygenase-2 (COX-2), responsible for the conversion of arachidonic acid into prostaglandin (PG) E2, is known to increase intracellular cAMP and estrogen production in malignant breast tissue. The aromatase enzyme complex is responsible for local production of estrogens in breast cancer. Increasing evidence supports a role for COX-2 in upregulation of aromatase activity. The aim of this study was to examine the relationship between COX-2 and aromatase mRNA expression in human breast cancer.
METHODS: A total of 160 breast samples (127 tumor tissues and 33 normal tissues) were analyzed. Levels of transcription were determined using real-time quantitative PCR. COX-2 and aromatase mRNA expression were normalized against CK19. Levels of expression of COX-2 were correlated with those of aromatase using Pearson's correlation method.
RESULTS: Levels of expression of COX-2/CK19 of both benign and malignant tissues were positively correlated with aromatase/CK19 transcript levels (correlation coefficient = +0.536, P < 0.0001). When we compared levels of expression of both genes in malignant samples only, there was a highly significant positive correlation (r = +0.611, P < 0.00001).
CONCLUSION: This study demonstrates a strong positive relationship between COX-2 and aromatase mRNA expression, and lends further support to the hypothesis that COX-2 is an upregulator of aromatase in breast tissue.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17657731     DOI: 10.1002/jso.20740

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  6 in total

1.  Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer.

Authors:  Louise R Howe; Kotha Subbaramaiah; Clifford A Hudis; Andrew J Dannenberg
Journal:  Clin Cancer Res       Date:  2013-08-19       Impact factor: 12.531

2.  Inhibition of cyclooxygenase-2 down-regulates aromatase activity and decreases proliferation of Leydig tumor cells.

Authors:  Rosa Sirianni; Adele Chimento; Arianna De Luca; Fabiana Zolea; Amalia Carpino; Vittoria Rago; Marcello Maggiolini; Sebastiano Andò; Vincenzo Pezzi
Journal:  J Biol Chem       Date:  2009-08-13       Impact factor: 5.157

3.  Radiation-enhancement of MDA-MB-231 breast cancer cell invasion prevented by a cyclooxygenase-2 inhibitor.

Authors:  B Paquette; H Therriault; G Desmarais; R Wagner; R Royer; R Bujold
Journal:  Br J Cancer       Date:  2011-07-26       Impact factor: 7.640

Review 4.  Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives.

Authors:  Ines Barone; Amanda Caruso; Luca Gelsomino; Cinzia Giordano; Daniela Bonofiglio; Stefania Catalano; Sebastiano Andò
Journal:  Obes Rev       Date:  2021-09-24       Impact factor: 10.867

5.  In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.

Authors:  Anne E Lykkesfeldt; Katrine L Henriksen; Birgitte B Rasmussen; Hironobu Sasano; Dean B Evans; Susanne Møller; Bent Ejlertsen; Henning T Mouridsen
Journal:  BMC Cancer       Date:  2009-06-16       Impact factor: 4.430

6.  Association between Cyclooxygenase-2 and Indoleamine 2,3-Dioxygenase Expression in Breast Cancer Patients from Pakistan.

Authors:  Kashif Asghar; Asif Loya; Iftikhar Ali Rana; Muhammad Abu Bakar; Asim Farooq; Muhammad Tahseen; Muhammad Ishaq; Muhammad Usman Rashid
Journal:  Asian Pac J Cancer Prev       Date:  2019-11-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.